An open-label, multicenter, phase I study of RP2 as a single agent and in combination with nivolumab in patients with solid tumors: Safety, efficacy, and biomarker results

K. J. Harrington,J. J. Sacco,A. Olsson-Brown, T. Chan, P. Nenclares, I. Leslie,P. Bommareddy, C. Ahlers, J. Wolff, M. R. Middleton

Annals of Oncology（2022）

引用 0|浏览1

暂无评分

摘要

RP2 is an enhanced potency oncolytic herpes simplex virus (HSV) -1 expressing GM-CSF, a fusogenic protein (GALV-GP R-), and an anti-CTLA-4 antibody-like molecule that is being evaluated in an open-label, multicenter, phase 1 clinical trial as monotherapy and combined with nivolumab (nivo). Here, we present updated safety, efficacy, and biomarker data of RP2 ± nivo.

查看译文

关键词

rp2,nivolumab,solid tumors,biomarker results,open-label

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要